NBIX vs. NVO
NBIX (Neurocrine Biosciences, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — NBIX in Drug Manufacturers - Specialty & Generic, NVO in Drug Manufacturers - General. Over the past 10 years, NBIX returned 13.16%/yr vs 7.56%/yr for NVO. At a 0.19 correlation, their price movements are largely independent.
Performance
NBIX vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 12.64% return, which is significantly higher than NVO's -10.74% return. Over the past 10 years, NBIX has outperformed NVO with an annualized return of 13.16%, while NVO has yielded a comparatively lower 7.56% annualized return.
NBIX
- 1D
- -1.81%
- 1M
- -0.97%
- YTD
- 12.64%
- 6M
- 4.55%
- 1Y
- 27.80%
- 3Y*
- 18.64%
- 5Y*
- 10.13%
- 10Y*
- 13.16%
NVO
- 1D
- -0.18%
- 1M
- -6.80%
- YTD
- -10.74%
- 6M
- -9.50%
- 1Y
- -43.34%
- 3Y*
- -15.59%
- 5Y*
- 2.92%
- 10Y*
- 7.56%
NBIX vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 12.64% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
NVO Novo Nordisk A/S | -10.74% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Correlation
The correlation between NBIX and NVO is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since May 23, 1996 | 0.19 |
Fundamentals
NBIX:
$16.52B
NVO:
$195.21B
NBIX:
$6.53
NVO:
DKK 27.42
NBIX:
24.46
NVO:
10.34
NBIX:
0.48
NVO:
0.44
NBIX:
5.27
NVO:
3.85
NBIX:
4.85
NVO:
6.21
NBIX:
$3.10B
NVO:
DKK 327.80B
NBIX:
$3.05B
NVO:
DKK 268.30B
NBIX:
$881.20M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. NVO — Risk / Return Rank
NBIX
NVO
NBIX vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.73 | ||
| Sortino ratioReturn per unit of downside risk | +2.42 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 0.85 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 1.34 | -0.80 | +2.14 |
| Martin ratioReturn relative to average drawdown | 2.94 | -1.18 | +4.12 |
Loading charts...
Drawdowns
NBIX vs. NVO - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NBIX and NVO.
Loading charts...
Drawdown Indicators
| NBIX | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -74.70% | -22.51% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -54.34% | +33.44% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -74.70% | +31.81% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -74.70% | +31.81% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -74.70% | +28.31% |
Current DrawdownCurrent decline from peak | -4.54% | -68.11% | +63.57% |
Average DrawdownAverage peak-to-trough decline | -43.84% | -17.79% | -26.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.49% | 37.62% | -28.13% |
Volatility
NBIX vs. NVO - Volatility Comparison
The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 9.63%, while Novo Nordisk A/S (NVO) has a volatility of 10.68%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.63% | 10.68% | -1.05% |
Volatility (6M)Calculated over the trailing 6-month period | 23.91% | 38.04% | -14.13% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.38% | 51.88% | -20.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.73% | 38.33% | -5.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.13% | 32.56% | +6.57% |
Dividends
NBIX vs. NVO - Dividend Comparison
NBIX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.11%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.11% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NBIX vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. NVO - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
NBIX and NVO have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVO has higher volatility (10.68%) compared to NBIX (9.63%). In terms of maximum drawdown, NBIX dropped -97.21% vs NVO's -74.70%.
NBIX currently has the higher Sharpe Ratio (0.89 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer